Drug Discovery 2022: driving the next life science revolution
Where: R3 R4 & R5 [Show on Floor Plan]
CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO. Join us on our journey to change the future of health: www.cellink.com.
Tel: +46 31128 700
Address: Långfilsgatan 5, Gothenburg, Sweden
Website: https://www.cellink.com/

Staff Attending

Miss Desislava Chukarska
Marketing Manager EU
Dr Andrew Ridley
Head of Sales (Europe)

Find out more...

To view the virtial stand - please login first LinkedIn URL